Safety Reading Notes

Read safety context beside the research guide.

The CBC and skin/dermatology source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 38777605

PubMed For Dummies Article

CBC and skin/dermatology Evidence Review: the long-form source walk-through

Quick read
  • CBC and skin/dermatology currently has 21 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 38777605
  • The evidence classes most visible in the row language are insufficient (11), mechanistic or pharmacological (6), preclinical (3), and preliminary human (1). PMID 42163693
  • The study-design language most visible in the row language is Cellular or in vitro study (5), Narrative or expert review (5), and Animal study (5). PMID 37630401
  • The repeated topics are Skin and inflammatory dermatology (21), which tells the reader where to start opening PubMed and DOI links. PMID 40580638

Start with the research question

CBC and skin/dermatology is built from 21 source-backed evidence row(s) and 21 research source(s). The current evidence classes read as insufficient (11), mechanistic or pharmacological (6), preclinical (3), and preliminary human (1), and the study-design language most often reads as Cellular or in vitro study (5), Narrative or expert review (5), and Animal study (5). PMID 38777605

The row-level question is not simply whether CBC and skin/dermatology is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are Skin and inflammatory dermatology (21). PMID 42163693

Human evidence 1 row

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 36916438

Preclinical evidence 3 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 38885660

Mechanistic evidence 6 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 38889235

Limits and uncertainty 11 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 27094344

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 39769302

Where this page has the most source density

The largest bucket surfaced for this page is Skin and inflammatory dermatology: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Skin and inflammatory dermatology: mechanistic or pharmacological, which gives readers another way to see what the literature repeatedly circles. PMID 38777605

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 42163693

Bucket chapters: what the literature is circling

Skin and inflammatory dermatology: insufficient

11 research sources 11 rows (701-719) Evidence class: insufficient

This bucket summarizes source-backed rows focused on Skin and inflammatory dermatology: insufficient. It currently draws from 11 research source(s), so the exact study type matters. PMID 38777605

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 38777605

  • Evidence row 701

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 38777605

  • Evidence row 719

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 38927152

Skin and inflammatory dermatology: mechanistic or pharmacological

6 research sources 6 rows (700, 707, 708, 711, 712, 713) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on Skin and inflammatory dermatology: mechanistic or pharmacological. It currently draws from 6 research source(s), so the exact study type matters. PMID 42163693

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 42163693

  • Evidence row 700

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin,... PMID 42163693

  • Evidence row 707

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin,... PMID 27094344

Skin and inflammatory dermatology: preclinical

3 research sources 3 rows (703, 704, 720) Evidence class: preclinical

This bucket summarizes source-backed rows focused on Skin and inflammatory dermatology: preclinical. It currently draws from 3 research source(s), so the exact study type matters. PMID 40580638

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 40580638

  • Evidence row 703

    CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory... PMID 40580638

  • Evidence row 704

    CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory... PMID 36916438

Skin and inflammatory dermatology: preliminary human

1 research source 717 Evidence class: preliminary human

This bucket summarizes source-backed rows focused on Skin and inflammatory dermatology: preliminary human. It currently draws from 1 research source(s), so the exact study type matters. PMID 41983582

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 41983582

  • Evidence row 717

    CBC studied for Skin and inflammatory dermatology; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory out... PMID 41983582

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (1 row(s)), mechanistic evidence (6 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 38777605

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 42163693

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 39457041
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 39596719
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 35628241

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 38777605

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 42163693

Source-reading checklist for CBC and skin/dermatology

  1. Open the linked PubMed or DOI record. PMID 37242431
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 36769042
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 35354487
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 41202683
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 41121423

Source Notes

CBC and skin/dermatology source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 700

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 42163693

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.
  2. Evidence row 701

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 38777605

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Potential of Cannabichromene (CBC) as a Therapeutic Agent.
  3. Evidence row 702

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 37630401

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.
  4. Evidence row 703

    CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 40580638

    Evidence class: preclinical; Study design: Animal study. Source: Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents.
  5. Evidence row 704

    CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 36916438

    Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
  6. Evidence row 705

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 38885660

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion.
  7. Evidence row 706

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 38889235

    Evidence class: insufficient. Source: Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation.
  8. Evidence row 707

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 27094344

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.
  9. Evidence row 708

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 39769302

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models.
  10. Evidence row 709

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 39457041

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors.
  11. Evidence row 710

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 39596719

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy Against Streptococcus and Staphylococcus.
  12. Evidence row 711

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 35628241

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.
  13. Evidence row 712

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 37242431

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol and Minor Phytocannabinoids: A Preliminary Study to Assess Their Anti-Melanoma, Anti-Melanogenic, and Anti-Tyrosinase Properties.
  14. Evidence row 713

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 36769042

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway.
  15. Evidence row 714

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 35354487

    Evidence class: insufficient. Source: Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: part 1 - continuous bivariate analysis.
  16. Evidence row 715

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 41202683

    Evidence class: insufficient. Source: Design and synthesis of amphiphilic cannabichromene derivatives with antimicrobial potential.
  17. Evidence row 716

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 41121423

    Evidence class: insufficient. Source: Targeting the antioxidant, antimicrobial and anti-inflammatory activity of non-psychotropic Cannabis sativa L.: a comparison with chemotype V.
  18. Evidence row 717

    CBC studied for Skin and inflammatory dermatology; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 41983582

    Evidence class: preliminary human. Source: Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens.
  19. Evidence row 718

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 37514074

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review.
  20. Evidence row 719

    CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 38927152

    Evidence class: insufficient. Source: Spent Material Extractives from Hemp Hydrodistillation as an Underexplored Source of Antimicrobial Cannabinoids.
  21. Evidence row 720

    CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 7298870

    Evidence class: preclinical; Study design: Animal study. Source: Biological activity of cannabichromene, its homologs and isomers.